目的 觀察雙丹明目膠囊聯(lián)合羥苯磺酸鈣分散片治療糖尿病視網(wǎng)膜病變的安全性和有效性。方法 選取2016年8月—2017年8月大連市第三人民醫(yī)院接診的糖尿病視網(wǎng)膜病變患者143例，隨機分成對照組（71例）和治療組（72例）。對照組患者口服羥苯磺酸鈣分散片，1片/次，3次/d；治療組患者在對照組治療基礎(chǔ)上口服雙丹明目膠囊，4粒/次，3次/d。兩組患者均連續(xù)治療4個月。觀察兩組患者臨床療效，同時比較治療前后兩組患者低視力者生活質(zhì)量評分量表（CLVQOL）評分、視野平均缺損程度和證候積分、血清脂聯(lián)素、胰島素樣生長因子1（IGF-1）、色素上皮衍生因子（PEDF）和不良反應(yīng)情況。結(jié)果 治療后，對照組臨床有效率為84.51%，顯著低于治療組的95.83%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者CLVQOL評分顯著升高（P<0.05），視野平均缺損程度和證候積分均顯著降低（P<0.05），且治療組患者CLVQOL評分、視野平均缺損程度、證候積分比對照組改善更明顯（P<0.05）。治療后，兩組患者血清脂聯(lián)素和PEDF水平均顯著升高（P<0.05），IGF-1水平顯著降低（P<0.05），且治療組患者血清脂聯(lián)素、IGF-1及PEDF水平比對照組改善更明顯（P<0.05）。治療期間，治療組患者不良反應(yīng)發(fā)生率為2.78%，明顯低于對照組的12.68%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 雙丹明目膠囊聯(lián)合羥苯磺酸鈣分散片治療糖尿病視網(wǎng)膜病變療效顯著，不良反應(yīng)發(fā)生率低，具有一定的臨床推廣應(yīng)用價值。

Objective To observe the clinical safety and efficacy of Shuangdan Mingmu Capsules combined with Calcium Dobesilate Dispersible Tablets in treatment of diabetic retinopathy. Methods Patients (143 cases) with diabetic retinopathy in the Third People's Hospital of Dalian from August 2016 to August 2017 were randomly divided into control (71 cases) and treatment (72 cases) groups. Patients in the control group were po administered with Calcium Dobesilate Dispersible Tablets, 1 tablet/time, three times daily. Patients in the treatment group were po administered with Shuangdan Mingmu Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 4 months. After treatment, the clinical efficacy was evaluated, and the CLVQOL score, mean visual field defect, syndrome scores, serum adiponectin, IGF-1, PEDF and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 84.51%, which was significantly lower than 95.83% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the CLVQOL scores in two groups were significantly increased (P<0.05), but mean visual field defect and syndrome scores were significantly decreased (P<0.05), and these indicators in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the serum adiponectin and PEDF levels in two groups were significantly increased (P<0.05), but IGF-1 levels were significantly decreased (P<0.05), and the serum adiponectin, IGF-1 and PEDF levels in the treatment group were significantly better than those in the control group (P<0.05). During the treatment, the adverse reactions rate in the treatment group was 2.78%, which was significantly lower than 12.68% in the control group, with significant difference between two groups (P<0.05). Conclusion Shuangdan Mingmu Capsules combined with Calcium Dobesilate Dispersible Tablets has significant curative effect in treatment of diabetic retinopathy with low incidence of adverse reactions, which has a certain clinical application value.